O-1812 is an
eicosanoid derivative related to
anandamide that acts as a potent and highly selective
agonist for the
cannabinoid receptorCB1, with a
Ki of 3.4 nM at CB1 and 3870 nM at
CB2.[1] Unlike most related compounds, O-1812 is metabolically stable against rapid breakdown by enzymes, and produces a cannabinoid-like discriminative effect in rats, which is similar but not identical to that produced by cannabinoid drugs of other chemical classes.[2][3][4][5]
^Di Marzo V, et al. (February 2001). "Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands". Biochemical and Biophysical Research Communications. 281 (2): 444–51.
doi:
10.1006/bbrc.2001.4354.
PMID11181068.
^Baskfield CY, Martin BR, Wiley JL (April 2004). "Differential effects of Δ9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 86–91.
doi:
10.1124/jpet.103.055376.
PMID14718593.
S2CID36621393.
^Wiley JL, Smith FL, Razdan RK, Dewey WL (March 2005). "Task specificity of cross-tolerance between Δ9-tetrahydrocannabinol and anandamide analogs in mice". European Journal of Pharmacology. 510 (1–2): 59–68.
doi:
10.1016/j.ejphar.2005.01.006.
PMID15740725.
O-1812 is an
eicosanoid derivative related to
anandamide that acts as a potent and highly selective
agonist for the
cannabinoid receptorCB1, with a
Ki of 3.4 nM at CB1 and 3870 nM at
CB2.[1] Unlike most related compounds, O-1812 is metabolically stable against rapid breakdown by enzymes, and produces a cannabinoid-like discriminative effect in rats, which is similar but not identical to that produced by cannabinoid drugs of other chemical classes.[2][3][4][5]
^Di Marzo V, et al. (February 2001). "Highly selective CB1 cannabinoid receptor ligands and novel CB1/VR1 vanilloid receptor "hybrid" ligands". Biochemical and Biophysical Research Communications. 281 (2): 444–51.
doi:
10.1006/bbrc.2001.4354.
PMID11181068.
^Baskfield CY, Martin BR, Wiley JL (April 2004). "Differential effects of Δ9-tetrahydrocannabinol and methanandamide in CB1 knockout and wild-type mice". The Journal of Pharmacology and Experimental Therapeutics. 309 (1): 86–91.
doi:
10.1124/jpet.103.055376.
PMID14718593.
S2CID36621393.
^Wiley JL, Smith FL, Razdan RK, Dewey WL (March 2005). "Task specificity of cross-tolerance between Δ9-tetrahydrocannabinol and anandamide analogs in mice". European Journal of Pharmacology. 510 (1–2): 59–68.
doi:
10.1016/j.ejphar.2005.01.006.
PMID15740725.